## Clinical Diagnosis The patient presents with classic herpes zoster (shingles): dermatomal vesicular eruption with severe pain and systemic symptoms in an immunocompetent host. ## Antiviral Selection for Herpes Zoster **Key Point:** Valacyclovir and famciclovir are the preferred agents for herpes zoster in immunocompetent patients because they achieve higher intracellular acyclovir triphosphate concentrations and require less frequent dosing than acyclovir. **High-Yield:** Valacyclovir is the L-valyl ester prodrug of acyclovir; it has superior oral bioavailability (~54% vs 15–20% for acyclovir) and is converted to acyclovir by first-pass hepatic metabolism. ## Comparison of Nucleoside Analogues for Zoster | Agent | Dosing (Zoster) | Bioavailability | Frequency | Clinical Use | |-------|-----------------|-----------------|-----------|---------------| | Acyclovir | 800 mg 5× daily | 15–20% | QID–5× daily | Mild zoster; IV for severe/disseminated | | Valacyclovir | 1000 mg 3× daily | ~54% | TDS | **First-line for immunocompetent zoster** | | Famciclovir | 500 mg 3× daily | ~77% | TDS | Alternative first-line; similar efficacy | | Ganciclovir | IV only | — | BD | CMV; not indicated for VZV in immunocompetent | **Clinical Pearl:** In immunocompetent patients with zoster, valacyclovir and famciclovir reduce pain duration and post-herpetic neuralgia (PHN) incidence more effectively than oral acyclovir, making them preferred agents [cite:Harrison 21e Ch 187]. ## Treatment Principles 1. **Timing:** Initiate within 72 hours of rash onset (this patient is at day 3—still within window). 2. **Duration:** 7 days standard for immunocompetent hosts. 3. **Adjuncts:** Consider analgesics (NSAIDs, gabapentin) for pain control. **Mnemonic:** **VAL-FAM-ACY** — *Valacyclovir and Famciclovir are first-line; Acyclovir is older, less frequent dosing with newer agents.*
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.